Benjamin Hébraud

Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome

Murielle Roussel, Valérie Lauwers‐Cancès, Nelly Robillard et al. · Journal of Clinical Oncology · 2014 · 265 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults

M.L. Piel-Julian, Matthieu Mahévas, Johanne Germain et al. · Journal of Thrombosis and Haemostasis · 2018 · 136 citations · Full text

Medicine, Hematology, Immunology +15

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

Thierry Façon, Gordon Cook, Saad Z. Usmani et al. · Leukemia · 2022 · 123 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Marie‐Lorraine Chrétien, Jill Corre, Valérie Lauwers‐Cancès et al. · Blood · 2015 · 115 citations

Life Sciences, Genetics, Oncology +12

Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells

Cédric Menard, Joëlle Dulong, David Roulois et al. · Stem Cells · 2019 · 107 citations · Full text

Life Sciences, Cell Biology, Immunology +15